Zheng Chen

Zheng Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XXXuexia Xie
Xuexia Xie
FWFan Wu
Fan Wu
JTJiaxin Tian
Jiaxin Tian
ZLZhilong Liu
Zhilong Liu
HHHuibin He
Huibin He
CLCaiyong Lai
Caiyong Lai
As one of the most common cancer chemotherapy drugs, cisplatin is widely used in cancer management. However, cisplatin‐induced nephrotoxicity occurs in patients who receive this drug. This study is aimed at developing therapeutic agents that effectively alleviate the nephrotoxic effects during cisplatin treatment. We identified a compound named pyrocatechol (PCL) from a natural product library that significantly alleviated cisplatin‐induced cytotoxicity in vitro. Pyrocatechol treatment substantially ameliorated cisplatin (20 mg · kg-1) treatment‐induced neuropathological indexes, including inflammatory cell infiltration and apoptosis, in vivo. Mechanistically, pyrocatechol significantly prevented oxidative stress‐induced apoptosis by activating glutathione peroxidase 4 (GPX4) to reduce reactive oxygen species (ROS) accumulation in cisplatin‐treated cells. In addition, pyrocatechol significantly inhibited ROS‐induced JNK/P38 activation. Thus, we found that pyrocatechol prevents ROS‐mediated JNK/P38 MAPK activation, apoptosis, and cytotoxicity through GPX4. Our study demonstrated that pyrocatechol is a novel therapeutic agent against cisplatin‐induced kidney injury.

14 January 2024 in Andrology
Verified
Journal Article
Closed access
FSFu Shi
Fu Shi
YLYe Liu
Ye Liu
ZCZheng Chen
Zheng Chen
DLDongliang Li
Dongliang Li
YYYuanqing Yao
Yuanqing Yao
DCDandan Cao
Dandan Cao

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZCZheng Chen
Zheng Chen
TQTao Qi
Tao Qi
XQXiao-Ping Qin
Xiao-Ping Qin
JWJue Wang
Jue Wang
ZHZhang-Sen Huang
Zhang-Sen Huang
YZYumin Zhuo
Yumin Zhuo
The small nucleolar RNA host gene 12 (SNHG12) has been reported to play an important role in the tumorigenesis and progression of PCa, but the functional underlying mechanism has not been studied clearly. We detected the expression level of SNHG12 in PCa tissues and matched adjacent normal tissues that were collected from 85 patients. Then, colony formation assays, MTT experiments, and flow cytometry were used to examine the effect of SNHG12 on proliferation, cell cycle distribution, and apoptosis of DU145 cells. Further, Transwell invasion assay was utilized to assess whether SNHG12 participates in PCa cell invasion and affects the secretion of VEGF secretion in DU145 cells. Finally, we investigated the effect of SNHG12 on tumor growth in vivo. We found that SNHG12 promoted cell proliferation and suppressed apoptosis in PCa cells, which suggests that SNHG12 is probably a novel PCa biomarker and therapy target of PCa.

10 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
XQXiao-Ping Qin
Xiao-Ping Qin
QLQi-Ji Lu
Qi-Ji Lu
CYCheng-Huizi Yang
Cheng-Huizi Yang
JWJue Wang
Jue Wang
JCJian-Fan Chen
Jian-Fan Chen
YZYumin Zhuo
Yumin Zhuo
Background: This study determined the predictive value of CRMP4 promoter methylation in prostate tissues collected by core needle biopsies for a postoperative upgrade of Gleason Score (GS) to ≥8 in patients with low-risk PCa.Method: A retrospective analysis of the clinical data was conducted from 631 patients diagnosed with low-risk PCa by core needle biopsy at multiple centers and then underwent Radical Prostatectomy (RP) from 2014-2019. Specimens were collected by core needle biopsy to detect CRMP4 promoter methylation. The pathologic factors correlated with the postoperative GS upgrade to ≥8 were analyzed by logistic regression. The cut-off value for CRMP4 promoter methylation in the prostate tissues collected by core needle biopsy was estimated from the ROC curve in patients with a postoperative GS upgrade to ≥8.Result: Multivariate logistic regression showed that prostate volume, number of positive cores, and CRMP4 promoter methylation were predictive factors for a GS upgrade to ≥8 (OR: 0.94, 95% CI: 0.91-0.98, P=0.003; OR: 3.16, 95% CI: 1.81-5.53, P<0.001; and OR: 1.43, 95% CI: 1.32-1.55, P18.00%, the low-risk PCa patients were more likely to escalate to high-risk patients. The predictive sensitivity and specificity were 86.9% and 98.8%, respectively. The area under the ROC curve (AUC) was 0.929 (95% CI: 0.883-0.976; P18.0% and postoperative GS upgrade to ≥8 than in patients without an upgrade (P ≤ 0.002).Conclusion: A CRMP4 promoter methylation rate >18.00% in prostate cancer tissues indicated that patients were more likely to escalate from low-to-high risk after undergoing an RP. We recommend determining CRMP4 promoter methylation before RP for low-risk PCa patients.


17 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
ZCZheng Chen
Zheng Chen
TQTao Qi
Tao Qi
XQXiaoping Qin
Xiaoping Qin
JWJue Wang
Jue Wang
ZHZhangsen Huang
Zhangsen Huang
YZYumin Zhuo
Yumin Zhuo
The authors have withdrawn this preprint due to author disagreement.